Business Context and Reporting Period
Company: TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.)
Reporting Period: Quarter ended June 30, 2024 (Q2 2024)
Business Overview: A clinical-stage biopharmaceutical company focused on developing MYMD-1 (an oral TNF-α inhibitor for sarcopenia and autoimmune diseases) and Supera-CBD (a synthetic CBD analog). The company has no product revenue and relies on financing to fund operations.
Recent Corporate Actions: The company changed its name and ticker symbol to TNF Pharmaceuticals, Inc. (TNFA) in July 2024. It also completed a 1-for-30 reverse stock split in February 2024 and raised capital through private placements of Series F-1 and Series G Convertible Preferred Stock in May 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(9,565,648) | $(4,167,653) | $(19,365,689) | $(5,679,385) |
| Net Loss Attributable to Common Stockholders | $(10,342,988) | $(4,541,449) | $(21,344,896) | $(6,211,514) |
| Loss Per Share (Basic & Diluted) | $(4.54) | $(3.22) | $(9.58) | $(4.43) |
| Cash and Cash Equivalents | $536,026 | N/A | $536,026 | N/A |
| Marketable Securities | $12,530,326 | N/A | $12,530,326 | N/A |
| Total Current Assets | $14,357,732 | N/A | $14,357,732 | N/A |
| Total Current Liabilities | $5,782,781 | N/A | $5,782,781 | N/A |
| Working Capital | $8,574,951 | N/A | $8,574,951 | N/A |
| Stockholders' Equity | $97,805 | N/A | $97,805 | N/A |
| Accumulated Deficit | $(123,321,963) | N/A | $(123,321,963) | N/A |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased significantly from $5.78 million in Q2 2023 to $3.37 million in Q2 2024. This reduction was driven by lower Research and Development (R&D) costs ($2.22M to $0.40M) due to the completion of the Phase II sarcopenia study, and reduced General and Administrative (G&A) expenses ($1.88M to $1.02M) due to workforce reductions.
- Non-Operating Items: The Net Loss increased primarily due to non-cash charges related to the issuance of new preferred stock. The company recorded a loss of $8.85 million on the issuance of Series F-1 and Series G Convertible Preferred Stock in Q2 2024. This was partially offset by a $2.70 million gain on the change in fair value of warrant liabilities.
- Capital Structure: The company raised approximately $14 million in gross proceeds through the issuance of Series F-1 and Series G Preferred Stock in May 2024. This increased marketable securities significantly compared to the prior year period.
- Equity Position: Stockholders' equity is critically low at $97,805, despite a working capital surplus, due to a large accumulated deficit and the classification of significant preferred stock as mezzanine equity.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Capital Resources: Management believes current resources (cash and marketable securities totaling ~$13.1 million) are sufficient to fund operations for the next 12 months. However, the company has a history of operating losses and relies on future financing.
- Preferred Stock Obligations: The company has significant obligations to holders of Series F, F-1, and G Preferred Stock. These include monthly amortization payments and dividends (10% per annum, compounding monthly, potentially rising to 15% upon a "Triggering Event"). Payments can be made in cash or stock, but cash payments could deplete resources, while stock payments cause dilution.
- Unusual Items:
- Warrant Reclassification: In Q2 2024, Series F Warrants were reclassified from liabilities to equity following an amendment, resulting in a $7.96 million adjustment to additional paid-in capital and a $7.09 million loss recognized in the period.
- Executive Separations: The company recorded severance and accelerated stock-based compensation expenses related to the departure of the President/CMO and other executives.
- Risks:
- Dilution: Anti-dilution provisions (full ratchet) in preferred stock and warrant agreements could significantly lower conversion/exercise prices in future financings, leading to substantial dilution.
- Regulatory Approval: No revenue is expected until MYMD-1 or Supera-CBD receive regulatory approval and are commercialized.
- Going Concern: While management asserts sufficiency of funds for 12 months, the company has an accumulated deficit of over $123 million and requires additional capital for future clinical trials.
Investor Verification Checklist
- Cash Burn Rate: Verify the actual monthly cash burn rate against the $13.1 million in liquid assets to confirm the 12-month runway assertion.
- Preferred Stock Terms: Review the specific "Triggering Events" that would increase dividend rates to 15% and the conditions under which the company is forced to pay in cash versus stock.
- Warrant Liability Volatility: Assess the impact of future stock price fluctuations on the fair value of remaining warrant liabilities (Series F-1 and G), which are currently classified as liabilities and impact net income.
- Authorized Shares: Confirm the status of the July 2024 shareholder approval to increase authorized shares, which is necessary to satisfy potential conversion and warrant exercise obligations.
- Related Party Transactions: Review the terms of the Series G placement involving PharmaCyte Biotech, Inc., where the Chairman of the Board serves as an executive.